However, the addition of buparlisib to paclitaxel in HR-positive, HER2-negative advanced breast cancer patients in the phase II/III BELLE-4 trial did not improve PFS in all or PI3K pathway-activated study populations, and the trial was stopped for futility at the end of phase II [35]. Here, PIK3CA is linked to breast cancer.